Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury CHICAGO and TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, is pleased to announce receipt of a commercial viability analysis conducted by the Boston…

Source

Previous articleMINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer
Next articleField Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality